The FDA approved the mesenchymal stromal cell therapy remestemcel-L-rknd for some pediatric patients as young as 2 months. The U.S. Food and Drug Administration (FDA) has approved remestemcel-L-rknd (Ryoncil) for the treatment of...
The FDA approved ensartinib for certain patients with locally advanced or metastatic non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove) for adults with non-small cell lung cancer...
The FDA approved cosibelimab-ipdl for certain skin cancers that cannot be treated with surgery or radiation. The U.S. Food and Drug Administration (FDA) has approved cosibelimab-ipdl (Unloxcyt) for the treatment of adult patients with...
The FDA approved durvalumab for some patients with previously treated limited-stage small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) for the treatment of adults with limited-stage...
The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for the treatment of adult...
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic human epidermal...
The FDA Project Renewal initiative has updated the approved indications for fludarabine phosphate chemotherapy in chronic lymphocytic leukemia. The U.S. Food and Drug Administration (FDA) has approved updated labeling of fludarabine phosphate (Fludarabine Phosphate...
The FDA approved revumenib, a first-in-class menin inhibitor, to treat acute leukemias with a KMT2A translocation. The U.S. Food and Drug Administration (FDA) has approved revumenib (Revuforj) for the treatment of adult and pediatric...
The cell-based immunotherapy was approved for adults with relapsed or refractory acute lymphoblastic leukemia. The U.S. Food and Drug Administration (FDA) has approved obecabtagene autoleucel (Aucatzyl) for the treatment of adults with relapsed or...
The therapeutic was approved for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to asciminib (Scemblix) for adults with newly diagnosed, Philadelphia chromosome (Ph)-positive...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now